FLC
ZYNE

Fifth Lane Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Fifth Lane Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$127K – 270
2023
Q3 		$127K Buy
+100,000
New +$87.3K 0.04% 113

Fifth Lane Capital's ZYNE Position: Q4 2023 in Review

Fifth Lane Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 100,000 shares — an estimated $127K sold.

Fifth Lane Capital first reported a position in ZYNE in Q3 2023 and held it in 1 quarter. The position peaked at $127K in Q3 2023. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • Fifth Lane Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • Fifth Lane Capital sold 100,000 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $127K.
  • Fifth Lane Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2023 and held it in 1 quarter.
  • Fifth Lane Capital's Zynerba Pharmaceuticals, Inc position peaked at $127K in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Fifth Lane Capital's 13F filing for Q4 2023, filed 14 Feb 2024.